Image Fusion and Calcification Raising in Trans Aortic Valve Implantation (TAVI)
Primary Purpose
Symptomatic Aortic Stenosis
Status
Withdrawn
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Image Fusion
Sponsored by
About this trial
This is an interventional other trial for Symptomatic Aortic Stenosis
Eligibility Criteria
Inclusion Criteria:
- All patients admitted in Nantes CHU for trans fermoral aortic valve replacement with SAPIEN 3® device
- Patient who accepted to participate to the study
Exclusion Criteria:
- Impossible written consent
- Judiciary protected people
- Minor
- Women of childbearing age without contraception
Sites / Locations
- Nantes University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Group "Fusion"
Group "Control"
Arm Description
Trans aortic valve replacement with usual procedure with the addition of computed tomography 3D images and calcification raising to the usual fluoroscopy images.
Trans aortic valve replacement with usual procedure
Outcomes
Primary Outcome Measures
Radiation exposure
Dose area product (cGy/cm2)
Secondary Outcome Measures
Contrast product
Contrast volume (mL) used during procedure
Full Information
NCT ID
NCT03247465
First Posted
August 9, 2017
Last Updated
September 20, 2021
Sponsor
Nantes University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT03247465
Brief Title
Image Fusion and Calcification Raising in Trans Aortic Valve Implantation
Acronym
TAVI
Official Title
Value of Fusion of 3D Images With 2D Images, Associated With Calcification Raising During Trans Aortic Valve Implantation Procedures
Study Type
Interventional
2. Study Status
Record Verification Date
September 2021
Overall Recruitment Status
Withdrawn
Why Stopped
The deadlines of the ethics committee being very long, the investigator finally wished not to carry out the project.
Study Start Date
September 13, 2017 (Actual)
Primary Completion Date
September 13, 2017 (Actual)
Study Completion Date
September 13, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Nantes University Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Aortic stenosis is one of the most common cardiology diseases. Trans aortic valve implantation (TAVI) has been developed since 2002, first to treat rejected patients from conventional surgery, then to treat high surgical risk patients and nowadays probably intermediate surgical risk patient. TAVI related complications are still recurrent and the investigators are searching a way to decrease them.
One of them could be image fusion, since it may decrease radiation exposure and contrast agent use. It may also improve valve placement position leading to decreased complications.
40 prospective and consecutive patients will be included. Participants will be divided into two groups: the 20 first included will be control group, the 20 following patients will be the fusion group. For control group TAVI procedure will be the usual one, for fusion group the procedure will be the usual one with addition of computed tomography 3D images fusion with fluoroscopy 2D images.
Main evaluation criteria will be radiation exposure, measured by dose area product (DAP). Secondary evaluation criterion will be procedural as contrast agent volume used, procedure duration, subjective usefulness of image fusion or procedure failure evaluated immediately after procedure. The investigators will also evaluated procedure induced complications as de novo pacemaker implantation, de novo left bundle branch, vascular complication, major bleeding, acute kidney failure, significant aortic regurgitation. These complications occurrence will be evaluated after 1 month follow up, during the usual following consultation.
Detailed Description
Aortic stenosis is one of the most common cardiology diseases. If untreated, symptomatic aortic stenosis rapidly leads to death. Most of the time, this disease affects old fragile people for whom conventional surgery is countered or very risky. That is why Trans aortic valve implantation has been developed since 2002, first to treat rejected patients from conventional surgery, then to treat high surgical risk patients and nowadays probably intermediate surgical risk patient. Indeed, thanks to prodigious technical and human progress, procedure induced complication have clearly decreased. But TAVI related complications are still recurrent and the investigators are searching a way to decrease them.
One of them could be image fusion, since it may decrease radiation exposure and contrast agent use correlated to acute kidney failure. It may also improve valve placement position, and the investigators know that many rhythmic (atrio-ventricular block) and valvular (significant aortic regurgitation) complications are partially due to placement mistakes. So the investigators hope that image fusion will decrease these complications.
The investigators will include 40 prospective and consecutive patients. Inclusion criterion will be all major patients admitted in Nantes CHU for transfemoral aortic valve replacement with SAPIEN® 3 valve. Exclusion criterion will be women of childbearing age without contraception, impossible written consent, judiciary protected people. After inclusion, patients will be divided into two groups: the 20 first included will be control group, the 20 following patients will be the fusion group. For control group TAVI procedure will be the usual one, for fusion group the procedure will be the usual one with addition of computed tomography 3D images fusion with fluoroscopy 2D images. The only difference during all patient medical care will be the addition of image fusion in fusion group. Before and after procedure, both groups will have the usual medical monitoring and the appropriated medical interventions to participants case.
Main evaluation criterion will be radiation exposure, measured by dose area product (DAP).
Secondary evaluation criterion will be procedural as:
contrast agent volume used (mL),
procedure duration (min),
subjective usefulness of image fusion evaluated on a 0 to 3 scale
procedure failure : death, more than one valve implantation, valve dysfunction (mean trans-valvular gradient > 20 mmHg or moderate to severe aortic regurgitation) These criterions will be evaluated immediately after procedure.
The investigators will also evaluated procedure induced complications as:
de novo pacemaker implantation
de novo left bundle branch
non minor vascular complication on VARC-2 definition
major bleeding (BARC 3 or 5)
acute kidney failure (AKIN 2 or 3)
significant aortic regurgitation ≥ 2/4 These complications occurrence will be evaluated after 1 month follow up, during the usual following consultation with echocardiography.
Then differences between will be tested with appropriated statistical methods.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Symptomatic Aortic Stenosis
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The 20 first included patients will be control group, the 20 following patients will be the fusion group.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Group "Fusion"
Arm Type
Experimental
Arm Description
Trans aortic valve replacement with usual procedure with the addition of computed tomography 3D images and calcification raising to the usual fluoroscopy images.
Arm Title
Group "Control"
Arm Type
No Intervention
Arm Description
Trans aortic valve replacement with usual procedure
Intervention Type
Other
Intervention Name(s)
Image Fusion
Intervention Description
Addition of computed tomography 3D images and calcification raising to the usual fluoroscopy images.
Primary Outcome Measure Information:
Title
Radiation exposure
Description
Dose area product (cGy/cm2)
Time Frame
Immediately post procedure
Secondary Outcome Measure Information:
Title
Contrast product
Description
Contrast volume (mL) used during procedure
Time Frame
Immediately post procedure
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
All patients admitted in Nantes CHU for trans fermoral aortic valve replacement with SAPIEN 3® device
Patient who accepted to participate to the study
Exclusion Criteria:
Impossible written consent
Judiciary protected people
Minor
Women of childbearing age without contraception
Facility Information:
Facility Name
Nantes University Hospital
City
Nantes
ZIP/Postal Code
44093
Country
France
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Image Fusion and Calcification Raising in Trans Aortic Valve Implantation
We'll reach out to this number within 24 hrs